ASHP therapeutic position statement on the safe use of pharmacotherapy for obesity management in adults

American Journal of Health-System Pharmacy

Volumn 58, Issue 17, 2001, Pages 1645-1655

[No Author Info available]

Author keywords

American Society of Health System Pharmacists; Anorexics; Clinical studies; Contraindications; Drug interactions; Gastrointestinal drugs; Obesity; Orlistat; Phentermine; Sibutramine hydrochloride monohydrate; Toxicity

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEPRAMONE; AMPHETAMINE DERIVATIVE; BENZPHETAMINE; DEXFENFLURAMINE; FENFLURAMINE; MAZINDOL; METHAMPHETAMINE; PHENDIMETRAZINE; PHENMETRAZINE; PHENTERMINE; PHENTERMINE RESIN; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

BEHAVIOR THERAPY; CHEMOTHERAPY; CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; HEADACHE; HUMAN; LETHARGY; LONG TERM CARE; OBESITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SOMNOLENCE; TREATMENT INDICATION; WEIGHT REDUCTION;

EID: 0035449446     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/58.17.1645     Document Type: Review

References (58)

1. Overweight and obesity in the United States: Prevalence and trends, 1960-1994
2. Medical hazards of obesity
3. Actual causes of death in the United States
4. Social and economic effects of body weight in the United States
5. Health-related quality of life in obese persons seeking treatment
6. Obesity
7. A 33-year-old woman with morbid obesity
8. Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40-64 years
9. The new era of drug treatment. Pharmacologic treatment of obesity: Symposium overview
10. Use and abuse of appetite-suppressant drugs in the treatment of obesity
11. Long-term pharmacotherapy in the management of obesity
12. Sibutramine. A review of its contribution to the management of obesity
13. Orlistat
14. Promising new approaches to the management of obesity
15. Treatment of affective disorder and obesity with topiramate
16. Clozapine weight gain, plus topiramate weight loss
17. New weight loss tool
18. Comparison of continuous and intermittent anorectic therapy in obesity
19. Long-term weight control studies I-VII
20. International trial of long-term dexfenfluramine in obesity
21. Sibutramine produces dose-related weight loss
22. Long term weight loss with sibutramine
23. Long-term maintenance of weight loss after a very-low-calorie diet: A randomized blinded trial of the efficacy and tolerability of sibutramine
24. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients
25. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat
26. Valvular heart disease associated with fenfluramine-phentermine
27. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine
28. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: US Department of Health and Human Services interim public health recommendations
29. Absence of cardiac valve dysfunction in obese patients treated with sibutramine
30. Appetite-suppressant drugs and the risk of primary pulmonary hypertension
31. Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine
32. Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors
33. The serotonin syndrome: Implicated drugs, pathophysiology, and management
34. Randomized, double-blind trial of chitosan for body weight reduction
35. Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent
36. Phenylpropanolamine and the risk of hemorrhagic stroke
37. Adverse events associated with ephedrine-containing products - Texas, December 1993-September 1995
38. Rapidly progressive interstitial renal fibrosis in young women: Association with slimming regimen including Chinese herbs
39. Ma-huang strikes again: Ephedrine nephrolithiasis
40. Acute hepatitis associated with the use of a Chinese herbal product, ma-huang
41. Hepatitis after germander (Teucrium chamaedrys) administration: Another instance of herbal medicine hepatotoxicity
42. Second thought about safety of St. John's wort
43. Herb-drug interactions
44. Safety of St. John's wort (Hypericum perforatum)
45. Content versus label claims in ephedra-containing dietary supplements
46. Herbal medicinals
47. Herbs as medicines
48. Pharmacist counseling on nutrition and physical activity - Part 1 of 2: Understanding current guidelines
49. Pharmacist counseling on nutrition and physical activity - Part 2 of 2: Helping patients make changes
50. Weight reduction in osteoarthritis using phentermine
51. Role of orlistat in the treatment of obese patients with type 2 diabetes: A l-year randomized double-blind study